Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines.
They solved the CRISPR Cas12a structure, discovered how the unique Cas12a enzyme cuts DNA, and are now engineering superior variants for gene editing...
